Tesamorelin peptide benefits rest on unusually solid trial data, its side effects are documented rather than guessed at, and reported dosage sits in a narrow 1 to 2 mg daily band. That combination is rare in this category, and it changes how you should read everything that follows.
- Tesamorelin is a 44 amino acid analog of growth hormone releasing hormone (GHRH), stabilized with a trans-3-hexenoic acid group at the N-terminal tyrosine.
- It signals the pituitary to release growth hormone in pulses rather than supplying growth hormone directly, so the body's own feedback loop stays in the circuit.
- The strongest evidence is for visceral fat reduction, measured directly by imaging over roughly six months in the trials that supported its approval for HIV-associated lipodystrophy.
- Reported research dosing runs 1 to 2 mg subcutaneously once daily, most often fasted, across cycles of 12 to 26 weeks.
- Fluid retention, joint aching, injection site reactions and a small upward drift in fasting glucose are the effects that show up consistently.
What Tesamorelin Actually Is
Tesamorelin belongs to the GHRH analog class, the same family as sermorelin and CJC-1295. Where it differs is structural. Native human GHRH is 44 amino acids long and falls apart in plasma within a few minutes, which makes it useless as a therapeutic on its own. Tesamorelin keeps the full 44 amino acid backbone and adds a trans-3-hexenoic acid group to the tyrosine at position one. That single modification shields the molecule from the enzymes that would otherwise clip it, extending how long it survives in circulation from a few minutes to a window long enough to drive a full pituitary response.
Compare that to sermorelin, which is only the first 29 residues of GHRH and is cleared faster still. Both bind the same receptor, but the longer tesamorelin remains intact, the more of that receptor occupancy translates into an actual hormone pulse, which is the mechanistic reason a single dose produces a larger and more reproducible response. Our sermorelin peptide guide covers the shorter fragment separately.
The mechanism is upstream, and that is the whole point. The molecule docks onto GHRH receptors in the anterior pituitary, and the gland empties part of its own stored growth hormone within minutes. Hepatic tissue reads that pulse and answers with IGF-1, and it is IGF-1, not growth hormone itself, that carries out most of what people are actually after: fat oxidation and tissue repair. Injecting recombinant growth hormone skips all of that and holds IGF-1 flat. Tesamorelin does not, and the preserved pulsatility is the main argument in its favor.
One framing note. Tesamorelin is approved as a pharmaceutical under the brand name Egrifta for a specific indication. The lyophilized vials sold to researchers are not that product and are supplied for laboratory research only. Everything below describes what has been reported in research settings, not a protocol for anyone to follow.
Tesamorelin Benefits
Because tesamorelin went through full Phase III development, the evidence here is stratified in a way it rarely is for research peptides. Worth separating the tiers honestly.
Visceral fat reduction. Strong human evidence. The registration trials enrolled adults with HIV-associated lipodystrophy and excess abdominal adiposity, and measured visceral adipose tissue directly rather than inferring it from weight. Deep abdominal fat fell significantly against placebo over the six-month treatment window. Two details matter more than any headline number. First, the loss was selective: subcutaneous fat and lean mass were largely preserved, which is unusual for any fat loss intervention. Second, the effect reversed. When treatment stopped, visceral fat drifted back toward baseline over a comparable window, which tells you the mechanism is maintenance-dependent rather than a permanent reset.
IGF-1 and growth hormone axis elevation. Strong, and directly measurable. Trial participants showed IGF-1 climbing well above baseline, which is exactly what a working GHRH signal should produce. This is the one benefit anyone can verify with a blood draw rather than a mirror, and it is the cleanest way to confirm a given vial is doing anything at all.
Liver fat. Promising, narrower evidence base. Randomized work in people with HIV and fatty liver reported reductions in liver fat content. The proposed mechanism, growth hormone driven hepatic fat oxidation, has no obvious reason to be HIV-specific, but the trials were run in that population and extrapolation to the general fatty liver population is not yet supported by equivalent data.
Cognitive measures. Interesting, thin, and easy to overstate. Some controlled work in older adults has looked at memory and executive function during growth hormone axis stimulation, with encouraging but limited results. IGF-1 receptors are present in the hippocampus and prefrontal cortex, so a plausible mechanism exists, but this is a small literature and anyone presenting tesamorelin as a cognitive enhancer is running well ahead of it.
Lipid markers, sleep and recovery. Secondary and largely inferential. Triglycerides and the triglyceride to HDL ratio improved in the visceral fat trials, most likely as a consequence of the fat loss rather than a direct drug effect. Deeper sleep and faster training recovery are reported consistently and fit what growth hormone does, but they were not primary endpoints.
What tesamorelin does not do is worth stating plainly. It is not a strong subcutaneous fat loss agent, so the visible leanness people associate with growth hormone protocols is muted when it is run alone. It is not meaningfully anabolic in the way androgens are. And it does not work quickly. The trial endpoints sat at 26 weeks for a reason.
Tesamorelin Side Effects
The side effect profile is milder than exogenous growth hormone, and the reason is structural rather than lucky. Because the pituitary is still regulating output, IGF-1 climbs to a high-normal range instead of overshooting it, which keeps the classic growth hormone problems off the table at typical doses.
The effects reported most often:
- Injection site reactions. A red patch, itching, a small firm lump, or brief soreness. The most frequent complaint by a wide margin, and heavily influenced by needle technique and whether sites are rotated.
- Fluid retention and peripheral edema. Puffiness in the hands, feet or face, typically appearing in the first one to two weeks and settling within two to three as the body adjusts to the new growth hormone level. The scale can move up slightly during this phase while fat mass has not changed at all.
- Joint aching and stiffness. Small load-bearing joints in the hands and lower limbs complain first. Onset around weeks two to four, dose-dependent, and generally the first thing to improve when a dose is lowered.
- Paresthesia. Tingling or numbness in the hands and feet, related to the same fluid shifts rather than nerve damage, and usually transient.
- Muscle aching and headache. Less common, generally mild, and often confounded with the fluid retention phase.
- Nausea. Uncommon, mostly post-injection, and reported more with fasted morning dosing.
The glucose question deserves its own paragraph because it is the one effect with a real mechanistic basis rather than a nuisance profile. Growth hormone is counter-regulatory to insulin. Trials recorded small increases in fasting glucose in some participants. For metabolically healthy people this rarely amounted to anything clinically relevant, and the visceral fat reduction pushes in the opposite direction over time, potentially offsetting it. For anyone already insulin resistant, prediabetic or diabetic, that offset cannot be assumed, and this is the parameter most worth tracking.
Where the data is genuinely thin: long-term use beyond a year, use in people without a clinical indication, and the theoretical concern that sustained IGF-1 elevation could support growth of an existing malignancy. Trials did not show increased cancer incidence over their duration, but their duration was months, not decades. Tesamorelin is contraindicated in active malignancy and in known pituitary lesions, and there is no research population that establishes what indefinite use looks like.
Tesamorelin Dosage Chart
Every figure below is a reported research range drawn from published trial protocols and documented use. None of it is a recommendation, and there is no established dosing standard for use outside the approved indication.
| Context | Reported range | Frequency | Typical cycle |
|---|---|---|---|
| Tolerance assessment / conservative entry | 1 mg | Once daily, subcutaneous | 2 to 4 weeks |
| Intermediate step-up | 1.5 mg | Once daily, subcutaneous | 4 to 8 weeks |
| Clinical-style visceral fat protocol | 2 mg | Once daily, subcutaneous | 26 weeks (3 to 6 months) |
| General growth hormone axis support | 1 to 2 mg | Once daily, subcutaneous | 12 to 26 weeks |
| Paired with a GHRP | 1 mg tesamorelin + 200 to 300 mcg ipamorelin | Once daily, subcutaneous | 12 weeks and up |
| Intermittent variant | 1 to 2 mg | 5 days on, 2 days off | 3 to 6 months |
A note on the 1 mg versus 2 mg discrepancy you will see across sources. The approved pharmaceutical dose is 2 mg daily, and that is the dose the published visceral fat outcomes were built on. The widespread 1 mg starting point is not a formal protocol step; it is a tolerability practice meant to blunt early edema and joint discomfort. Both numbers are real, but citing 1 mg while quoting the 2 mg outcome data conflates them.
Timing has the clearest mechanistic rationale of any variable here. Somatostatin is the brake on growth hormone release, insulin encourages the hypothalamus to apply it, and a recent meal therefore costs pulse amplitude. That is why reported protocols cluster around a stomach that has been empty for a couple of hours, which in practice means before breakfast or well clear of the evening meal.
On cycling: the registration program extended past the six-month endpoint without the pituitary becoming refractory, so the case for mandatory breaks is weaker than it is usually presented. The practical arguments for 3 to 6 months on with a break are cost, the chance to assess whether anything changed, and caution about a duration nobody has studied. Serial IGF-1 testing is the only objective way to confirm a response.
Stacking
The one combination with a genuine pharmacological rationale is a GHRH analog paired with a growth hormone releasing peptide. They act on separate systems: tesamorelin drives the GHRH receptor directly, while a GHRP like ipamorelin works through the ghrelin receptor and suppresses somatostatin, the brake on growth hormone release. Releasing the brake while pressing the accelerator produces a substantially larger pulse than either compound alone. Ipamorelin ends up being the default partner because of what it leaves alone: unlike GHRP-2 and GHRP-6, it is selective enough to skip the appetite spike and the cortisol and prolactin drift those two can carry. Our ipamorelin peptide guide covers that side of the pairing in detail.
What does not make sense is stacking tesamorelin with another GHRH analog. Sermorelin and CJC-1295 compete for the same receptor, so you are paying twice to occupy one site. With the DAC version of CJC-1295 there is an additional issue: its multi-day half-life produces a sustained elevation rather than discrete pulses, which works against the specific reason to choose tesamorelin in the first place.
Reconstitution and Storage
Tesamorelin arrives as a lyophilized powder, most often in 2 mg or 5 mg vials. It is reconstituted with bacteriostatic water, added slowly down the inside wall of the vial rather than jetted directly onto the cake, then swirled gently. Shaking shears peptide chains and is the single most common handling error.
Concentration is a choice, not a fixed value. Putting 1 mL into a 2 mg vial yields 2 mg/mL, so a full 1 mL draw is one 2 mg dose. Putting 2 mL in yields 1 mg/mL, which makes partial doses far easier to measure accurately on an insulin syringe. For anyone titrating between 1 mg and 2 mg, the lower concentration is the more forgiving option.
Unreconstituted vials are stable refrigerated for the manufacturer's stated shelf life. Once reconstituted, refrigerate immediately, protect from light, expect roughly 28 to 30 days of usable stability, and do not freeze. Because tesamorelin is dosed daily, a vial gets punctured far more often than a twice-weekly peptide, so clean stopper technique matters more here than usual.
How to Verify What You Buy
GHRH analogs are unforgiving of degradation. A vial that has been heat-stressed or poorly synthesized will not stimulate a pulse, and there is no subjective symptom that reliably tells you the difference between a bad vial and a non-responder. Ask any supplier for third-party testing that identifies the peptide and quantifies purity, and check that the report corresponds to the batch you were actually shipped rather than a generic sample. Our where to buy tesamorelin page walks through which suppliers publish verifiable testing, and the tesamorelin for sale listing tracks current vial sizes and pricing so you can sanity check anything that looks unusually cheap.
Frequently Asked Questions
What does tesamorelin peptide do?
It stimulates the anterior pituitary to release its own growth hormone by binding GHRH receptors, which in turn raises IGF-1. The best-documented downstream effect is a selective reduction in visceral abdominal fat, with subcutaneous fat and lean mass largely spared. It does not supply growth hormone directly, so the body's normal pulsatile rhythm and negative feedback stay intact.
Is tesamorelin safe?
Within the trial populations and durations studied, the safety profile was manageable and clearly milder than exogenous growth hormone. Fluid retention, joint discomfort, injection site reactions and a modest rise in fasting glucose account for most of what was observed. The honest caveats are that safety data comes from a specific clinical population over months rather than years, that it is contraindicated in active malignancy and pituitary lesions, and that research-grade material carries an entirely separate set of risks around identity and purity that no trial addresses.
How much tesamorelin is used in research?
Reported ranges are 1 to 2 mg subcutaneously once daily, with 2 mg being the dose behind the published visceral fat outcomes and 1 mg commonly used as a tolerability starting point. Cycles in the literature run 12 to 26 weeks, and the pivotal work extended beyond that. These are reported figures, not guidance, and no dosing standard exists for use outside the approved indication.
Is tesamorelin legal?
Tesamorelin is an approved prescription drug in the United States under the brand name Egrifta, indicated for excess abdominal fat in HIV-associated lipodystrophy, and obtaining that product legitimately requires a prescription. Research-grade tesamorelin in lyophilized vials is legal to buy and possess for laboratory research, but it is not approved for human use and marketing it for human consumption is not lawful. Rules vary by country, so check your own jurisdiction.
